A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients by Debing, Yannick et al.
Accepted Manuscript
A Mutation in the Hepatitis E Virus RNA Polymerase Promotes its Replication and
Associates with Ribavirin Treatment Failure in Organ Transplant Recipients
Yannick Debing, Anett Gisa, Kai Dallmeier, Sven Pischke, Birgit Bremer, Michael
Manns, Heiner Wedemeyer, Pothakamuri Venkata Suneetha, Johan Neyts
PII: S0016-5085(14)01079-8
DOI: 10.1053/j.gastro.2014.08.040
Reference: YGAST 59323
To appear in: Gastroenterology
Accepted Date: 5 August 2014
Please cite this article as: Debing Y, Gisa A, Dallmeier K, Pischke S, Bremer B, Manns M, Wedemeyer
H, Suneetha PV, Neyts J, A Mutation in the Hepatitis E Virus RNA Polymerase Promotes its Replication
and Associates with Ribavirin Treatment Failure in Organ Transplant Recipients, Gastroenterology
(2014), doi: 10.1053/j.gastro.2014.08.040.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
All studies published in Gastroenterology are embargoed until 3PM ET of the day they are published as
corrected proofs on-line. Studies cannot be publicized as accepted manuscripts or uncorrected proofs.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
A Mutation in the Hepatitis E Virus RNA Polymerase 
Promotes its Replication and Associates with Ribavirin 
Treatment Failure in Organ Transplant Recipients 
Short title: Enhanced HEV fitness in ribavirin failure 
Authors: Yannick Debing1†, Ane Gisa²†, Kai Dallmeier1, Sven Pischke3, Birgit Bremer², Michael 
Manns², Heiner Wedemeyer²§, Pothakamuri Venkata Suneetha²§, Johan Neyts1 
1 Rega Institute for Medical Research, Department of Microbiology and Immunology, University of 
Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium 
2 Department of Gastroenterology, Hepatology and Endocrinology, Center of Internal Medicine, 
Hannover Medical School, Carl-Neubergstraße 1, 30625 Hannover, Germany 
3 MVZ für Lebertransplantation, University Hospital Hamburg Eppendorf, Martinistraße 52, 20246 
Hamburg, Germany 
† contributed equally, § contributed equally 
Grant support: Yannick Debing is a fellow of the Research Foundation – Flanders (FWO). This work is 
supported by KU Leuven, geconcerteerde onderzoeksactie (GOA/10/014) and EU FP7 project SILVER 
(260644), a special fund on HEV by the Robert-Koch-Institute to HW and SP (1362-1097) and the 
German Federal Ministry for Education and Research (01E00802). 
Abbreviations: ALT, alanine aminotransferase; EC50, 50% effective concentration; γGT, γ-
glutamyltransferase; HEV, hepatitis E virus; RBV, ribavirin; RT-qPCR, reverse-transcription 
quantitative polymerase chain reaction; wt, wild-type. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
Correspondence: Johan Neyts - Rega Institute for Medical Research - Department of Microbiology 
and Immunology - Minderbroedersstraat 10 - 3000 Leuven – Belgium - Tel. +32-16-33.73.41 - Fax. 
+32-16-33.73.40 - Email: johan.neyts@rega.kuleuven.be 
Disclosures: Nothing to disclose 
Author contributions: Study concept and design: YD, AG, KD, HW, PVS, JN; Acquisition of data: YD, 
AG, SP, BB, PVS; Data analysis: YD, AG, HW, PVS, JN; Drafting of manuscript: YD, AG, PVS; Revision of 
manuscript: KD, SP, MM, HW, JN. 
Acknowledgements: We would like to thank Hendrik Thibaut, David Franco and Suzanne Kaptein for 
helpful discussions, Steve Fitzgerald and Natalie Nelissen for editorial help, Patrick Behrendt for 
retrieving clinical data and Patrick Lehmann for technical assistance. We are grateful to Ralf 
Bartenschlager, Luc Verschaeve and Suzanne U. Emerson for supplied materials. We thank all 
physicians and nurses involved at Hannover Medical School in treating patients with hepatitis E. We 
are most grateful to all patients who agreed to provide material for this study. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
Abstract 
We analyzed blood samples collected from 15 patients with chronic hepatitis E who were recipients 
of solid-organ transplants. All patients cleared the hepatitis E virus (HEV) except for 2 
(nonresponders); 1 patient died. A G1634R mutation in viral polymerase was detected in the HEV 
RNA of the non-responders; this mutation did not provide the virus with resistance to ribavirin in 
vitro. However, the mutant form of a subgenomic replicon of genotype 3 HEV replicated more 
efficiently in vitro than HEV without this mutation, and the same was true for infectious virus, 
including in competition assays. Similar results were obtained for genotype 1 HEV. The G1634R 
mutation therefore appears to increase the replicative capacity of HEV in the human liver and hence 
reduce the efficacy of ribavirin. 
Keywords: RNA-dependent RNA polymerase; virulence; drug resistant; mechanism 
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Hepatitis E virus (HEV) is a feco-orally transmitted RNA virus and a common cause of acute hepatitis 
worldwide.
1,2
 Genotypes 1 and 2 cause water-borne outbreaks in developing countries and 
exclusively infect humans, whereas genotypes 3 and 4 are zoonotic and consumption of undercooked 
pig meat is the most documented route of transmission.
1,3
 Although HEV infections are often 
asymptomatic, they can manifest as acute hepatitis, but usually resolve spontaneously. However, 
genotype 3 infections may evolve to chronicity in immunocompromised patients, e.g. transplant or 
HIV patients,
4,5
 and may lead to cirrhosis, graft loss and death.
6
 Ribavirin (RBV) monotherapy is the 
treatment-of-choice for most patients.
7,8
 However, treatment failure has been observed, either as a 
partial response to ribavirin or viral recurrence after therapy cessation, and is possibly linked to dose 
reductions because of severe anemia in some cases.
7,8 
We report on 15 solid-organ-transplant patients with chronic hepatitis E (11 with genotype 3c, 3 
genotype 3f and 1 genotype 3e). RBV treatment was successful in all but 2 patients (both genotype 
3c) who failed to clear the virus (13%, which is comparable  to other studies reporting failure rates of 
15-18%).
7,8
 The first patient was a male heart/kidney-recipient who was treated for 9 months and 
showed an initial decrease in viral RNA load upon initiation of RBV treatment but never became HEV 
RNA negative (i.e. below 1000 copies/mL, Figure 1A). Nevertheless, after 4 months of RBV therapy, 
HEV RNA loads increased again to baseline levels (even before a transient dose reduction because of 
anemia) and persisted over time. The patient died of hepatic decompensation as described 
previously.
9
 The second patient is a female lung/kidney/bone-marrow-recipient who underwent two 
consecutive RBV treatments of 4 and 7 months respectively.
10
 Although at the end of each treatment 
period, HEV RNA status was negative, viral RNA was detected again shortly after stopping therapy. 
ALT levels normalized rapidly, but γGT remained above normal and strongly increased during the 
second RBV course (Figure 1B). To explore the underlying causes of non-responsiveness to RBV in 
both patients, complete HEV genome sequences before, during and after treatment were compared. 
In both patients, a unique G-to-A nucleotide substitution was identified resulting in a G1634R 
mutation in the C-terminal region of the HEV polymerase. Comparison of HEV sequences in GenBank 
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revealed that K1634 was the predominant amino acid in genotype 1 and 4, whereas in genotype 3 
G1634 was more common (77%) than R1634 (22%, mostly subgenotypes 3e-f) (Figure 1C, 
Supplementary Table 1). 
Since the clinical course and evolution of viral loads was reminiscent of antiviral resistance 
development, the 1634R mutation was introduced into a genotype 3 replicon and its sensitivity to 
RBV was compared to that of the wild-type (wt) replicon.
11
 No difference in RBV sensitivity was 
observed, with calculated EC50-values of 5.1±3.7 and 5.1±4.1 µM for G1634 and 1634R respectively 
(Figure 1D). The 1634R construct however consistently yielded higher luminescence signals than its 
wt counterpart, suggesting increased viral RNA replication. To further explore this, two hepatoma 
cell lines were transfected with capped replicon RNA for wt, 1634R and 1634K (predominant in 
genotype 1). In Huh7 cells, the 1634R construct resulted in a 3.4-fold increase in luminescence signal 
compared to the G1634 construct (P=0.04) and the 1634K construct yielded a 2.7-fold higher signal 
than wt (P=0.07, Figure 1E). In HepG2/C3A cells, both mutants resulted in a significantly increased 
signal: 1.6-fold for 1634R (P=0.02) and 2.1-fold for 1634K (P=0.02) (Figure 1E). Similar results were 
obtained when 10:1, 1:1 or 1:10 mixtures of wt and/or mutant RNA were tested (Supplementary 
Figure 1). 
Next, the impact of the 1634R/K mutations on replication and production of viral progeny of full-
length genotype 3 was studied by transfection of Huh7 cells and quantification of released viral RNA. 
The 1634R and 1634K variants replicated to higher titers than the wt at every time point studied 
(Figure 2A). When treated with RBV at 10 or 25 µM, replication was partially reduced, but 
nevertheless the same pattern in relative replication efficiency was observed for the 3 variants. 
Intracellularly, viral RNA copies per µg RNA were at least 2-fold higher for 1634R/K compared to 
G1634 (Figure 2B). In untreated HepG2/C3A cells, a comparable pattern was observed, although 
somewhat less pronounced than in Huh7 cells (Supplementary Figure 2). Treatment of transfected 
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HepG2/C3A cells with RBV at 10 or 25 µM resulted in a strong inhibition of viral replication so that no 
differences could be observed. 
To compare the fitness of G1634 and 1634R variants, replication was analyzed in direct competition 
assays. To this end, cells were transfected with mixtures of G1634:1634R full-length RNA in 10:1, 1:1 
or 1:10 ratios (90, 50 and 10% G respectively) and were cultured for 20 days. The evolution of the 
fraction of both variants released into the culture medium was monitored by allele-specific RT-qPCR. 
The proportion of G1634 was experimentally confirmed to be 12±1, 45±1 and 88±1% in the input 
RNA and decreased to respectively 2.2±0.4, 17±1 and 61±2% in Huh7 and 2±2, 18±4 and 64±2% in 
HepG2/C3A cells (Figure 2C). This corresponds to a relative fitness gain for 1634R of 7-9% over 20 
days and up to 15% for the first 10 days. A similar pattern was noted in cell lysates (P<0.001, Figure 
2D, Supplementary Figure 3). These results provide a strong indication that for genotype 3, 1634R 
has an increased fitness compared to G1634. 
To determine the influence of the 1634 mutations on viral fitness in other genotypes, a genotype 1 
replicon in Huh7 cells was employed in which the original K1634 was mutated to 1634R, 1634G, 
1634Q or 1634E. As expected, 1634G yielded a decreased signal compared to K1634 (0.7-fold, Figure 
2E). Surprisingly, the 1634R mutant also displayed decreased replication (0.8-fold), albeit not 
statistically significant. A single genotype 1 strain was found with Q1634 (Accession Number 
JF443723),
12
 but in our replicon, 1634Q decreased replication (0.5-fold, P=0.11). Introduction of two 
other mutations unique to this strain yielded replication-impaired or lethal phenotypes 
(Supplementary Figure 4). Finally, the 1634E mutant displayed a significantly reduced replication 
(0.4-fold, P=0.049) as expected, given that this is a negatively-charged amino acid, contrary to the 
positively-charged R and K. 
In conclusion, this is the first reported virulence mutation in the HEV genome that was confirmed in 
vitro. The increased replication capacity of the mutant may have contributed to the persistent 
disease courses despite RBV treatment, although other patient- and virus-related factors could have 
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contributed as well.
6,13
 It may be interesting to assess the possible use of position 1634 as a 
prognostic marker and accordingly to adjust dose and duration of ribavirin therapy based on the 
presence of the G1634R variant. 
 
Figure legends 
Figure 1. RBV treatment failure is associated with a G1634R mutation. (A-B) Clinical course and 
sequencing results for patients experiencing RBV failure; arrow indicates RBV dose reduction. (C) 
Prevalence of G, R and K at position 1634 per genotype. (D) G1634R does not alter RBV sensitivity. (E) 
Increased luminescence read-out in 1634R/K compared to G1634 in Huh7 and HepG2/C3A cells. 
*P<0.05, **P<0.01. 
Figure 2. 1634R/K has an increased fitness compared to G1634. (A) Kinetics of released genotype 3 
RNA indicate increased replication of 1634R/K strains compared to G1634, both in untreated or RBV-
treated cells. (B) Intracellular viral RNA reveals a similar pattern. (C) Mixtures of G1634 and 1634R 
full-length RNA were transfected into Huh7 or HepG2/C3A cells and the fraction of wt G1634 in 
released viral RNA was monitored, indicating outcompeting of G1634 by 1634R. (D) Comparing input 
RNA with intracellular viral RNA 20 days post transfection shows a similar decrease in the G1634 
fraction. (E) In a genotype 1 replicon, replication is decreased for 1634G/R/Q/E compared to the wt 
K1634 in Huh7 cells. *P<0.05, ***P<0.001. 
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Supplementary materials and methods 1 
Study subjects 2 
All patients were recruited at Hannover Medical School between 2008 and 2014. Serum samples 3 
were collected from 15 solid organ-transplanted (SOT) patients who developed chronic hepatitis E 4 
and received ribavirin (RBV) treatment. All patients were infected with genotype 3 HEV. Serum 5 
samples were collected before (I), during (II) and after RBV treatment (III). At least one serum sample 6 
from each time point (I-III) was used for further studies. Written informed consent was obtained 7 
from each patient included in this study. The study protocol conformed to the ethical guidelines of 8 
the Institutional Review Committee. 9 
RBV (Rebetol® or Copegus®) was administered orally twice daily with an initial daily dose of 600-10 
1000 mg, depending on the patients’ hemoglobin level and comorbidities.1 Dose reductions were 11 
performed if hemoglobin levels declined and/or patients developed symptoms associated with 12 
anemia. At each visit, aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-13 
glutamyltranspeptidase (γGT) as well as HEV serology and HEV RNA viremia were determined. Anti-14 
HEV status was determined using Wantai HEV IgG (Beijing, China). HEV RNA from serum was 15 
quantified by one-step RT-qPCR as described.2 All patients cleared HEV RNA by the end of treatment, 16 
except for 2 chronically infected transplant recipients (both infected with genotype 3c). 17 
Extraction and sequencing of HEV RNA from serum samples 18 
Total RNA was extracted from 200 µl of serum or EDTA-plasma using Cobas AmpliPrep total nucleic 19 
acid isolation kit (Roche, Basel, Switzerland). Total RNA concentration was measured using the 20 
NanoVue Plus spectrophotometer (GE Healthcare Life Sciences, Little Chalfont, UK). cDNA was 21 
synthesized from 4 to 8 μL of purified total RNA using the SuperScript III first-strand synthesis system 22 
(Life Technologies, Carlsbad, CA) with the external reverse primer from each set (set1-4 A2 (ex)) at a 23 
final concentration of 2 µM (see section Primers and probes). A touchdown nested PCR (n-PCR) with 24 
4 sets of specific external and internal primer pairs listed in the section Primers and probes was used 25 
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to amplify the coding regions of the HEV genome. The first PCR round was carried out with TaKaRa Ex 26 
Taq Hot Start Version (Dalian, China) using 8 μL of synthesized cDNA and an external primer pair at a 27 
final concentration of 1 µM each in a 50 μL reaction with 18 cycles of 30 s at 94°C, 45 s at 62°C with a 28 
reduction of 0.5°C/cycle and 1 min/kb at 72°C, followed by 14 cycles of 30 s at 94°C, 45 s at 53°C and 29 
1 min/kb at 72°C. A final extension of 10 min at 72°C followed the final cycle. The second PCR round 30 
was carried out using internal primer pairs and 5 μL of the first-round PCR product with identical 31 
amplification parameters to the first round. The resulting amplicons were separated by agarose gel 32 
electrophoresis and purified using Qiaquick gel extraction kit (Qiagen, Hilden, Germany) and 33 
concentrations were measured using NanoVue Plus spectrophotometer (for Sanger sequencing). 34 
Sanger sequencing and analysis of HEV coding regions 35 
The purified PCR products were sequenced commercially (GATC Biotech, Konstanz, Germany) in both 36 
forward and reverse directions using the internal primer pairs from set 1-4 (see section Primers and 37 
probes) on an automatic DNA sequencer (Sanger ABI 3730xl). To identify nucleotide and amino acid 38 
variations between different time points (before, during and after treatment) the nucleotide 39 
sequences from all sets were assembled using Sequencher 4.9 software by Gene Codes (Ann Arbor, 40 
MI). 41 
Cells, viruses and replicons 42 
Huh7 cells (a kind gift from Ralf Bartenschlager, University of Heidelberg, Germany) and HepG2/C3A 43 
cells (a kind gift from Luc Verschaeve, Scientific Institute of Public Health, Brussels, Belgium) were 44 
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Carlsbad, CA) supplemented with 45 
10% fetal bovine serum (FBS; Gibco) in a humidified 5% CO2 incubator at 37°C. 46 
Genotype 3 full-length and reporter replicon viral RNA was derived from plasmids encoding Kernow-47 
C1 p6 (GenBank accession number JQ679013) and Kernow-C1 p6/luc HEV strains respectively.3 48 
Genotype 1 replicon RNA was derived from Sar55/S17/luc-encoding plasmid.4 Both were kind gifts 49 
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from Suzanne U. Emerson (NIAID, NIH, Bethesda, MD). Amino acid numbering is according to NCBI 50 
reference sequence NP_056779. 51 
Site-directed mutagenesis and plasmid preparation 52 
Mutations were introduced by PCR amplification of overlapping fragments with specifically mutated 53 
primers. To introduce the 1634R mutation into the Kernow-C1 p6/luc replicon, PCR amplifications 54 
were performed with primer pairs KC1p6-AflII-5’f + KC1p6-1634Rr and KC1p6-1634Rf + KC1p6/luc-55 
NruI-3’r (see section Primers and probes for primer sequences). Consequently both fragments were 56 
combined in a fusion PCR with primers KC1p6-AflII-5’f and KC1p6/luc-NruI-3’r. PCRs were performed 57 
with KAPA HiFi HotStart ReadyMix PCR kit (Kapa biosystems, Wilmington, MA). The resulting 58 
fragment was digested with AflII, phosphorylated and ligated into AflII- and NruI-digested Kernow-C1 59 
p6/luc plasmid. Similarly, primer pairs KC1p6-AflII-5’f + KC1p6-1634Kr and KC1p6-1634Kf + 60 
KC1p6/luc-NruI-3’r were used to introduce the 1634K mutation. To mutate the full-length Kernow-C1 61 
p6 plasmid, PCRs were performed with the same primer sets except KC1p6-PmlI-3’r was used as the 62 
ultimate 3’-end primer. The resulting fusion fragment was digested with AflII, phosphorylated and 63 
ligated into AflII- and PmlI-digested Kernow-C1 p6 vector. 64 
To mutate the genotype 1 Sar55/S17/luc construct (wild-type (wt): K1634), PCRs were performed 65 
with primer pairs SarLuc-SfiI-5’f + SarLuc-1634Gr and SarLuc-1634Gf + SarLuc-NheI-3’r (1634G), 66 
SarLuc-SfiI-5’f + SarLuc-1634Rr and SarLuc-1634Rf + SarLuc-NheI-3’r (1634R), SarLuc-SfiI-5’f + SarLuc-67 
1634Er and SarLuc-1634Ef + SarLuc-NheI-3’r (1634E), SarLuc-SfiI-5’f + SarLuc-1634Qr and SarLuc-68 
1634Qf + SarLuc-NheI-3’r (1634Q), SarLuc-SfiI-5’f + SarLuc-1346Gr and SarLuc-1346Gf + SarLuc-NheI-69 
3’r (1346G), SarLuc-SfiI-5’f + SarLuc-1498Pr and SarLuc-1498Pf + SarLuc-NheI-3’r (1498P), SarLuc-SfiI-70 
5’f + SarLuc-1346Gr and SarLuc-1346Gf + SarLuc-1498Pr and SarLuc-1498Pf + SarLuc-NheI-3’r (1346G 71 
+ 1498P). Fragments were combined in fusion PCRs with primers SarLuc-SfiI-5’f and SarLuc-NheI-3’r 72 
and digested with NheI and SfiI. The resulting fragments were ligated into NheI- and SfiI-digested 73 
Sar55/S17/luc vector. 74 
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E. coli Top10 cells (Life Technologies) were transformed with ligated plasmids. Kernow-C1-related 75 
constructs were cultured in 500 mL of Super Broth with ampicillin and maxiprepped (Plasmid maxi 76 
kit, Qiagen). Sar55-related plasmids were cultured in 100 mL of LB medium with ampicillin and 77 
midiprepped (NucleoBond Xtra midi kit, Macherey-Nagel, Düren, Germany). The cloned regions in 78 
each of the constructs were sequenced to ensure that no additional mutations had been introduced. 79 
In vitro transcription and capping 80 
Viral RNA was in vitro transcribed from MluI- (Kernow-related) or BglII- (Sar55-related) linearized 81 
plasmid DNA with the RiboMAX Large Scale RNA Production System-T7 (Promega, Madison, WI) and 82 
capped with the ScriptCap m7G capping system (Cellscript, Madison, WI). A firefly luciferase-based 83 
transfection control was generated as described.5 Nucleic acid concentrations were determined by 84 
spectroscopy (Nanodrop ND-1000, Thermo Fischer Scientific, Waltham, MA). 85 
Antiviral assay 86 
Luminescence-based antiviral assays were performed essentially as described.5 RBV [1-(β-D-87 
ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide (Virazole®)] was purchased from ICN Pharmaceuticals 88 
(Costa Mesa, CA). A stock solution was prepared in DMSO and stored at 4°C. 89 
Replicon assays 90 
Huh7 and HepG2/C3A cells were seeded into 6-well plates at 2x105 cells per well and transfected 91 
with capped RNA transcripts (1 µg per well) 24h later using Lipofectin (Life Technologies) according 92 
to the manufacturer’s instructions. After 72h of incubation at 35°C, Gaussia luciferase activity was 93 
measured in 20 µL of culture medium with the Renilla luciferase assay system (Promega). 94 
For replicon competition assays, Huh7 and HepG2/C3A cells were seeded into 12-well plates at 8x104 95 
cells per well. RNA was produced for each wt and mutant Kernow-C1 p6/luc replicon and 2 types of 96 
uncapped RNA were mixed in 10:1, 1:1 and 1:10 ratios. Mixtures were capped and 0.4 µg per well 97 
was transfected into cells 24h after seeding with Lipofectin. After 72h of incubation at 35°C, Gaussia 98 
luciferase activity was determined. 99 
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Full-length HEV replication kinetics and competition assays 100 
To determine the growth kinetics of wt and mutant full-length HEV (G1634, 1634R and 1634K), Huh7 101 
and HepG2/C3A cells were seeded into 6-well plates at 2x105 cells per well and transfected with 102 
capped RNA transcripts for Kernow-C1 p6 wt or mutants (1 µg per well). DMSO (0.125%) or RBV at 10 103 
or 25 µM were included in the culture medium. One mL of the medium was removed every 2-3 days, 104 
stored at -80°C until RNA extraction and 1mL of fresh medium (with DMSO or RBV) was added to 105 
each well. After 20 days, cell layers were lysed and intracellular RNA was extracted with the Qiagen 106 
RNeasy kit. To extract viral RNA from culture medium, RNase A (Promega) was added to 100 µL of 107 
thawed medium to a final concentration of 200 ng/mL and incubated at room temperature for 5’ to 108 
reduce the amount of residual in vitro transcripts from RNA transfection. Viral RNA was extracted 109 
with the NucleoSpin RNA virus kit (Macherey-Nagel) and quantified by reverse transcription 110 
quantitative PCR (RT-qPCR). 111 
For infectious virus competition assays, Huh7 and HepG2/C3A cells were seeded into 6-well plates at 112 
2x105 cells per well. RNA was produced for Kernow-C1 p6 wt and 1634R mutant and was mixed in 113 
10:1, 1:1 and 1:10 ratios. Mixtures were capped and transfected with Lipofectin into cells 24h after 114 
seeding. One mL of the medium was removed every 2-3 days, stored at -80°C until RNA extraction 115 
and 1mL of fresh medium was added to each well. RNase treatment and RNA extractions were 116 
performed as described above. RNA extracts were analyzed by allele-specific multiplex RT-qPCR. 117 
Input RNA mixtures and RNA extracts from cell lysates were subjected to RT-PCR with primers KC1p6-118 
AflII-5’f and KC1p6-PmlI-3’r (Onestep RT-PCR kit, Qiagen) and subsequent Sanger sequencing with 119 
primer KC1p6-AflII-5’f (BigDye Terminator v3.1 cycle sequencing kit, Life Technologies) for 120 
semiquantitative assessment of the G1634 : 1634R ratio. For calculation of relative fitness gains, the 121 
fitness of G1634 and 1634R strains is considered 1 and 1+s respectively with s being the relative 122 
fitness gain. s is calculated as described.6 123 
RT-qPCR 124 
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Quantification of total HEV RNA was performed essentially as described with primers HEVqf and 125 
HEVqr and probe HEVqp.5 For absolute quantification of intracellular viral RNA, copy numbers were 126 
normalized to total RNA per sample as determined by spectroscopy. 127 
Allele-specific multiplex RT-qPCR was performed with primers KC1p6-asqf and KC1p6-asqr. As 128 
probes, KC1p6-asqpG and KC1p6-asqpR were used (see section Primers and probes). Reactions were 129 
performed with One-Step qRT-PCR mix (Eurogentec, Seraing, Belgium) in a final volume of 25 µL 130 
containing 375 nM of each primer, 125 nM of each probe and 5 µL of RNA sample using the ABI 7500 131 
Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) under following conditions: 30 min 132 
at 48°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Data were 133 
analyzed with ABI PRISM 7500 SDS software (version 1.3.1, Applied Biosystems). For absolute 134 
quantification, standard curves were generated using 10-fold dilutions of the cloned target cDNA. 135 
Concentrations of DNA standards were calculated by spectroscopy (for regular RT-qPCR) or RT-qPCR 136 
(for allele-specific multiplex RT-qPCR). In order to validate the allele-specific multiplex RT-qPCR, 137 
mixtures of G1634 and 1634R RNA were made in known ratios (0, 20, 40, 60, 80 and 100% wt) and 138 
analyzed. Results show a strong correlation between expected and experimentally obtained fractions 139 
of wt (R² = 0.9895, n = 3). 140 
 141 
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Primers for mutagenesis and in vitro studies 
Primer name Sequence 
KC1p6-AflII-5’f 5’-TGATCACTTAAGGGTTTCTGGAAGAAGC-3’ 
KC1p6-1634Rr 5’-TCAACCTTCGAAGGAAATCACAAACAG-3’ 
KC1p6-1634Kr 5’-TCAACTTTCGAAGGAAATCACAAACAG-3’ 
KC1p6-1634Rf 5’-CTGTTTGTGATTTCCTTCGAAGGTTGACGAACG-3’ 
KC1p6-1634Kf 5’-CTGTTTGTGATTTCCTTCGAAAGTTGACGAACG-3’ 
KC1p6/luc-NruI-3’r 5’-CGAAGTTGCTGGCCACGGCCAC-3’ 
KC1p6-PmlI-3’r 5’-GTGAATCAACATCAGGTACAGGGGCTG-3’ 
SarLuc-SfiI-5’f 5’-AGATCTGGCCGTTATGGCCGCCGCACAAAG-3’ 
SarLuc-1634Gr 5’-TGAGCCCGCGGAGAAAATCACTCACAG-3’ 
SarLuc-1634Rr 5’-TGAGCCTGCGGAGAAAATCACTCACAG-3’ 
SarLuc-1634Er 5’-TGAGCTCGCGGAGAAAATCACTCACAG-3’ 
SarLuc-1634Qr 5’-TGAGCTGGCGGAGAAAATCACTCACAG-3’ 
SarLuc-1634Gf 5’-CTGTGAGTGATTTTCTCCGCGGGCTCACGAATG-3’ 
SarLuc-1634Rf 5’-CTGTGAGTGATTTTCTCCGCAGGCTCACGAATG-3’ 
SarLuc-1634Ef 5’-CTGTGAGTGATTTTCTCCGCGAGCTCACGAATG-3’ 
SarLuc-1634Qf 5’-CTGTGAGTGATTTTCTCCGCCAGCTCACGAATG-3’ 
SarLuc-1346Gr 5’-GCTCGTACAATTCCCCGGTTGTAACC-3’ 
SarLuc-1346Gf 5’-GGTTACAACCGGGGAATTGTACGAGC-3’ 
SarLuc-1498Pr 5’-GCAGAATCCACGCAGGCCTTATAAGGTGG-3’ 
SarLuc-1498Pf 5’-CCACCTTATAAGGCCTGCGTGGATTCTGC-3’ 
SarLuc-NheI-3’r 5’-CAAGCAATGCTAGCACAGAGTGG-3’ 
HEVqf 5’-GGTGGTTTCTGGGGTGAC-3’ 
HEVqr 5’-AGGGGTTGGTTGGATGAA-3’ 
HEVqp 5’-6FAM-TGATTCTCAGCCCTTCGC-MGBNFQ-3’            (from Life Technologies) 
KC1p6-asqf 5’-TGCTGAGCAGCTACGTC-3’ 
KC1p6-asqr 5’-GGGCTAACTCCATAGACACG-3’ 
Primers for analysis of clinical samples 
Set Primer  Sequence 
1 Set1-S1 (ex) 5’-AGGCTCCTGGCATTACTACTG-3’ 
Set1-S2 (in) 5’-GCCTTGGCGAATGCTGTG-3’ 
Set1-A1 (in) 5’-GGCCGGGGATGTARTCACG-3’ 
Set1-A2 (ex) 5’-CGGCACTGRGCATARAACTG-3’ 
2 Set2-S1 (ex) 5’-ATGACATACCTYCGTGGYATTAG-3’ 
Set2-S2 (in) 5’-GTYGCYAATGAGGGKTGGAA-3’ 
Set2-A1 (in) 5’-TTGTGGTCTCTGTRAARGTRGCRCCCT-3’ 
Set2-A2 (ex) 5’-CRGCCGTRGCTATAATTGTRGTCT-3’ 
3 Set3-S1 (ex) 5’-GYTTTGCGGCCTTYACACCYCAYAC-3’ 
Set3-S2 (in) 5’-CGYCGTGTTGTKATTGAYGAGGC-3’ 
Set3-A1 (in) 5’-GRCCRGCAAAHCGCACYACAT-3’ 
Set3-A2 (ex) 5’-AACACARACCTGCGCRACATTCGT-3’ 
4 Set4-S1 (ex) 5’-CCTGGYACCCTYCTYTGGAAYAC-3’ 
Set4-S2 (in) 5’-TGGGYTGTATGCYGGTGTGGTRGT-3’ 
Set4-A1 (in) 5’-CAGCCGACGAAATCAATTCTG-3’ 
Set4-A2 (ex) 5’-CCCTTATCCTGCTGYGCATT-3’ 
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KC1p6-asqpG 5’-6FAM-TCCTTCGAG-ZEN-GGTTGACGA-IBFQ-3’ 
KC1p6-asqpR 5’-HEX-TCCTTCGAA-ZEN-GGTTGACGAA-IBFQ-3’ 
Restriction sites (or partial restriction sites) are underlined and mutated codons are in bold-type. All 143 
primers for quantification and analysis of clinical samples were purchased at Eurofins MWG Operon 144 
(Germany), while primers and probes for in vitro studies were purchased at Integrated DNA 145 
Technologies (Coralville, IA), unless otherwise indicated. K=G/T/U, M=A/C, R=A/G, S=C/G, W=A/T, 146 
Y=C/T/U, N=A/T/G/C, H=A/T/C, V=A/G/C, D=A/T/G. 6FAM, 6- fluorescein amidite; HEX, 147 
hexachlorofluorescein; IBFQ, Iowa black fluorescent quencher; MGBNFQ, minor groove-binding non-148 
fluorescent quencher; ZEN, internal quencher. 149 
Statistical analysis 150 
Results for all experiments are derived from at least 3 independent experiments and were analyzed 151 
by two-tailed Student t test. 152 
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Genotype Number of 
sequences 
Sequences with 
G1634 (%) 
Sequences with 
R1634 (%) 
Sequences with 
K1634 (%) 
1 76 0 (0) 2 (3) 73 (96) 
2 1 0 (0) 1 (100) 0 (0) 
3 103 79 (77) 23 (22) 1 (1) 
4 85 1 (1) 6 (7) 78 (92) 
Total 265 80 (30) 32 (12)  152 (57) 
Supplementary Table 1 – Prevalence of G, R and K at position 1634 per genotype: HEV sequences 
from genotypes 1 to 4 for which a sequence of the C-terminal RdRp was available were used to 
calculate the prevalence of each amino acid at position 1634. Sequences obtained through BLASTP 
alignment, genotyping based on phylogenetic grouping with known genotype sequences (ClustalW2). 
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Supplementary Figure legends 
Supplementary Figure 1. 1634R/K display increased replication compared to G1634 in a genotype 3 
replicon assay when mixtures of G1634 : 1634R (G:R), G1634 : 1634K (G:K) and 1634R : 1634K (R:K) in 
10:1, 1:1 or 1:10 ratios are transfected into Huh7 (A) or HepG2/C3A (B) cells. For Huh7, significant 
differences were found between 10:1 and 1:10 mixtures of G:R (p=0.006) and G:K (p=0.04). Results in 
HepG2/C3A cells were fully in line with this. *P<0.05, **P<0.01. 
Supplementary Figure 2. Effect of G1634R/K on full-length genotype 3 HEV replication in HepG2/C3A 
cells. (A) Kinetics of released viral RNA after transfection in untreated HepG2/C3A cells indicate an 
increased replication for 1634R/K strains compared to wt G1634. Treatment with RBV at 10 or 25 µM 
results in a strong inhibition of viral replication. As a result, no differences in replication can be 
observed. (B) Intracellular viral RNA from transfected HepG2/C3A cells reveals a similar pattern as in 
released RNA. The higher RNA levels observed in cells treated with 25 µM of RBV compared to 10 µM 
are due to cytostatic effects on HepG2/C3A cells at this concentration and thus a strong decrease in 
total cellular RNA. 
Supplementary Figure 3. Sequencing of input and intracellular viral RNA from competition assay. 
Mixtures of full-length G1634 and 1634R HEV RNA were transfected into Huh7 and HepG2/C3A cells. 
RT-PCR and subsequent Sanger sequencing were performed on input and intracellular viral RNA 20 
days post transfection to compare relative amounts of G and R at position 1634 (marked with arrow). 
A gradual increase in the fraction 1634R can be observed in all mixtures in both cell lines. 
Supplementary Figure 4. 1634Q and other unique mutations in a genotype 1 HEV replicon. Viral 
replication is impaired for 1634Q compared to wt K1634 and even further for a combination of 
1346G+1634Q (GQ). The combinations 1498P+1634Q (PQ) and 1346G+1498P+1634Q (GPQ) result in 
a lethal phenotype. *P<0.05. 
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